Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK6097608 |
Synonyms | |
Therapy Description |
GSK6097608 is a monoclonal antibody targeting the tumor transmembrane protein, CD96, which may lead to inhibition of downstream signaling upon binding to CD96-expressing immune cells, thereby restoring T cell and NK cell function, and potentially resulting in an antitumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK6097608 | GSK-6097608|GSK 6097608|Anti-CD96 Monoclonal Antibody GSK6097608 | GSK6097608 is a monoclonal antibody targeting the tumor transmembrane protein, CD96, which may lead to inhibition of downstream signaling upon binding to CD96-expressing immune cells, thereby restoring T cell and NK cell function, and potentially resulting in an antitumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04446351 | Phase I | Dostarlimab-gxly + GSK6097608 GSK6097608 | Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors | Recruiting | USA | CAN | 2 |